SNC-Lavalin Receives Phase I Contract of Rio Tinto Alcan's AP60 Aluminium Smelting Project

SNC-Lavalin is pleased to announce that it has now received the go-ahead for the implementation of the first phase of Rio Tinto Alcan's AP60 project in Saguenay-Lac-St-Jean, Quebec.

SNC-Lavalin, as a 50/50 joint venture partner with Hatch, will provide project management, engineering, procurement, construction management and pre-commissioning services to implement this new energy-efficient and cost-effective aluminum smelting technology (AP60) aimed at providing a 40% higher output per pot than at existing smelters.

SNC-Lavalin has been involved in the project since the initial development phase, which began in 2007. In addition to funds already invested, Rio Tinto Alcan has approved $758 million to complete the first phase of the AP60 plant, which will include 38 pots for an aluminum production capacity of 60,000 tonnes per year. The project also includes associated infrastructure for Phase 1 and future phases.

"We are extremely pleased to participate in this highly innovative aluminum smelting project," said Feroz Ashraf, Executive Vice-President, SNC-Lavalin Group Inc. "Our association with Rio Tinto Alcan is built on more than 50 years of successful teamwork at many of their largest facilities in Canada and elsewhere. Our execution plan, in line with that of Rio Tinto Alcan, is to work closely with local contractors, manufacturers and service providers to deliver the project on budget and schedule, and to the highest standards of quality and safety."

Design and construction activities are underway for Phase 1 and will be accelerated for an expected completion date of 2013.

Source: http://www.snclavalin.com/

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.